Rhett P. Ketterling, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Tel: +1 507 284 9617; Fax: +1 507 266 4972; e-mail: [email protected]

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Objectives: Current information is insufficient regarding the prevalence, cytogenetic details, JAK2 involvement, JAK2V617F mutational status, and clinicopathologic correlates of chromosome 9p24 abnormalities. The current study was designed to provide additional data in this regard. Methods: The Mayo Clinic cytogenetics database spanning the years 1989–2008 was screened for chromosome 9p24 abnormalities. Bone marrow (BM) morphology was re-reviewed and relevant clinical information retrospectively obtained. Structural abnormalities of JAK2 were examined by FISH and JAK2V617F mutation analysis. Results: Among 24 262 unique patient cytogenetic studies, chromosome 9p24 abnormalities were identified in 25 patients (∼0.06%): 12 with myeloid and 13 with lymphoid neoplasms. The associated karyotype was complex in 12 of the 13 lymphoid but in only four of the 12 myeloid cases. Archived BM was available in 23 cases that allowed additional FISH studies and JAK2V617F mutation analysis. FISH analysis disclosed JAK2 involvement in 10 patients including five myeloid and five lymphoid cases; the associated karyotype was complex in all the lymphoid but in none of the myeloid cases. Five patients displayed previously undescribed JAK2 translocations: t(8;9)(q22;p24), t(9;17)(p24;q23), t(4;9)(q25;p24), t(2;9)(p21;p24) and t(8;9)(q13;p24). JAK2-associated chromosomal translocations, in a non-complex karyotype setting, were documented in four patients, all of whom carried a diagnosis of myeloproliferative neoplasms (MPN) and harbored JAK2V617F. Two patients with diffuse large B cell lymphoma displayed complex karyotype and JAK2 amplification by FISH. Conclusions: Chromosome 9p24 abnormalities are rare and do not always involve JAK2. The subset with JAK2 translocations are usually associated with MPN and harbor JAK2V617F, suggesting a cause-effect relationship. The current study also describes five novel translocations involving JAK2.

References

1 James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–8.
10.1038/nature03546
CAS PubMed Web of Science® Google Scholar
2 Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–90.
10.1056/NEJMoa051113
CAS PubMed Web of Science® Google Scholar
3 Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–97.
10.1016/j.ccr.2005.03.023
CAS PubMed Web of Science® Google Scholar
4 Renneville A, Quesnel B, Charpentier A, et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20: 2067–70.
10.1038/sj.leu.2404405
CAS PubMed Web of Science® Google Scholar
5 Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH, JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006; 20: 971–8.
10.1038/sj.leu.2404206
CAS PubMed Web of Science® Google Scholar
6 Verstovsek S, Silver RT, Cross NC, Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 2006; 20: 2067.
10.1038/sj.leu.2404379
CAS PubMed Web of Science® Google Scholar
7 Vizmanos JL, Ormazabal C, Larrayoz MJ, Cross NC, Calasanz MJ. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia 2006; 20: 534–5.
10.1038/sj.leu.2404086
CAS PubMed Web of Science® Google Scholar
8 Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309–12.
10.1126/science.278.5341.1309
CAS PubMed Web of Science® Google Scholar
9 Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90: 2535–40.
10.1182/blood.V90.7.2535
CAS PubMed Web of Science® Google Scholar
10 Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wormann B, Haase D, Bohlander SK. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005; 44: 329–33.
10.1002/gcc.20235
CAS PubMed Web of Science® Google Scholar
11 Adelaide J, Perot C, Gelsi-Boyer V, Pautas C, Murati A, Copie-Bergman C, Imbert M, Chaffanet M, Birnbaum D, Mozziconacci MJ. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 2006; 20: 536–7.
10.1038/sj.leu.2404104
CAS PubMed Web of Science® Google Scholar
12 Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005; 24: 7248–52.
10.1038/sj.onc.1208850
CAS PubMed Web of Science® Google Scholar
13 Murati A, Gelsi-Boyer V, Adelaide J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005; 19: 1692–6.
10.1038/sj.leu.2403879
CAS PubMed Web of Science® Google Scholar
14 Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65: 2662–7.
10.1158/0008-5472.CAN-04-4263
CAS PubMed Web of Science® Google Scholar
15 Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008; 47: 884–9.
10.1002/gcc.20585
CAS PubMed Web of Science® Google Scholar
16 Mark HF, Sotomayor EA, Nelson M, Chaves F, Sanger WG, Kaleem Z, Caughron SK. Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. Exp Mol Pathol 2006; 81: 217–23.
10.1016/j.yexmp.2006.07.004
CAS PubMed Web of Science® Google Scholar
17 Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 2007; 35: 1668–76.
10.1016/j.exphem.2007.08.025
CAS PubMed Web of Science® Google Scholar
18 Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, Strehl S. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009; 23: 134–43.
10.1038/leu.2008.306
CAS PubMed Web of Science® Google Scholar
19 Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001; 30: 393–401.
10.1002/1098-2264(2001)9999:9999<::AID-GCC1105>3.0.CO;2-I
CAS PubMed Web of Science® Google Scholar
20 Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000; 60: 549–52.
CAS PubMed Web of Science® Google Scholar
21 Helias C, Struski S, Gervais C, Leymarie V, Mauvieux L, Herbrecht R, Lessard M. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genet Cytogenet 2008; 180: 51–5.
10.1016/j.cancergencyto.2007.09.010
CAS PubMed Web of Science® Google Scholar
22 Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093–6.
10.1182/blood-2003-05-1627
CAS PubMed Web of Science® Google Scholar
23 Brockman SR, Paternoster SF, Ketterling RP, Dewald GW. New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. Cancer Genet Cytogenet 2003; 145: 144–51.
10.1016/S0165-4608(03)00061-X
CAS PubMed Web of Science® Google Scholar
24 Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279–84.
10.1002/cncr.22663
CAS PubMed Web of Science® Google Scholar
25 Tanner SM, Austin JL, Leone G, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci USA 2001; 98: 13901–6.
10.1073/pnas.241525498
CAS PubMed Web of Science® Google Scholar
26 Taviaux S, Brunel V, Dupont M, Fernandez F, Ferraz C, Carbuccia N, Sainty D, Demaille J, Birg F, Lafage-Pochitaloff M. Simple variant t(8;21) acute myeloid leukemias harbor insertions of the AML1 or ETO genes. Genes Chromosomes Cancer 1999; 24: 165–71.
10.1002/(SICI)1098-2264(199902)24:2<165::AID-GCC12>3.0.CO;2-1
CAS PubMed Web of Science® Google Scholar
27 Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80: 1825–31.
10.1182/blood.V80.7.1825.1825
CAS PubMed Web of Science® Google Scholar
28 Nucifora G, Birn DJ, Erickson P, Gao J, LeBeau MM, Drabkin HA, Rowley JD. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood 1993; 81: 883–8.
10.1182/blood.V81.4.883.883
CAS PubMed Web of Science® Google Scholar
29 Wang HY, Tirado CA. t(8;21)(q22;q22) Translocation involving AML1 and ETO in B lymophoblastic leukemia. Hum Pathol 2010; 41: 286–92.
10.1016/j.humpath.2009.08.004
CAS PubMed Web of Science® Google Scholar
30 Baldus CD, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003; 102: 1613–8.
10.1182/blood-2003-02-0359
CAS PubMed Web of Science® Google Scholar
31 Walz C, Chase A, Schoch C, et al. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 2005; 19: 1005–9.
10.1038/sj.leu.2403712
CAS PubMed Web of Science® Google Scholar
32 Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Miyamoto S, Ogura T, Ochiai A, Esumi H. Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 2004; 23: 7067–75.
10.1038/sj.onc.1207963
CAS PubMed Web of Science® Google Scholar
33 Drieschner N, Kerschling S, Soller JT, Rippe V, Belge G, Bullerdiek J, Nimzyk R. A domain of the thyroid adenoma associated gene (THADA) conserved in vertebrates becomes destroyed by chromosomal rearrangements observed in thyroid adenomas. Gene 2007; 403: 110–7.
10.1016/j.gene.2007.06.029
CAS PubMed Web of Science® Google Scholar
34 Meloni-Ehrig A, Smith B, Zgoda J, Greenberg J, Perdahl-Wallace E, Zaman S, Mowrey P. Translocation (2;8)(q35;q13): a recurrent abnormality in congenital embryonal rhabdomyosarcoma. Cancer Genet Cytogenet 2009; 191: 43–5.
10.1016/j.cancergencyto.2009.01.010
CAS PubMed Web of Science® Google Scholar
35 Plo I, Nakatake M, Malivert L, De Villartay JP, Giraudier S, Villeval JL, Wiesmuller L, Vainchenker W. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008; 112: 1402–12.
10.1182/blood-2008-01-134114
CAS PubMed Web of Science® Google Scholar
36 Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435–7.
10.1182/blood-2006-04-018259
CAS PubMed Web of Science® Google Scholar
37 Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676–82.
10.1182/blood-2005-09-3826
CAS PubMed Web of Science® Google Scholar
38 Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22: 4189–201.
10.1128/MCB.22.12.4189-4201.2002
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume84, Issue6

June 2010

Pages 518-524

Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates

Abstract

References

Citing Literature

References

Related

Information